NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00378-4715-22 | 00378-4715 | prednisolone | Prednisolone Sodium Phosphate | 15.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 8, 2014 | Dec. 31, 2018 | In Use |
00378-4730-22 | 00378-4730 | prednisolone | Prednisolone Sodium Phosphate | 30.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 8, 2014 | June 30, 2019 | In Use |
72064-0210-12 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-60 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-90 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
63020-0536-30 | 63020-0536 | ponatinib hydrochloride | Iclusig | 10.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan. 11, 2021 | In Use | |
50242-0105-01 | 50242-0105 | polatuzumab vedotin | POLIVY | 140.0 mg/7.52mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | June 10, 2019 | In Use | |
50242-0103-01 | 50242-0103 | polatuzumab vedotin | POLIVY | 30.0 mg/1.88mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Sept. 18, 2020 | In Use | |
00574-0792-01 | 00574-0792 | pilocarpine hydrchloride | pilocarpine hydrchloride | 5.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Cholinergic Agonist | Oral | Aug. 24, 2020 | In Use | |
65597-0402-20 | 65597-0402 | pexidartinib | Turalio | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Aug. 2, 2019 | In Use | |
65597-0402-28 | 65597-0402 | pexidartinib | Turalio | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Aug. 2, 2019 | In Use | |
65219-0371-10 | 65219-0371 | pegflilgrastim-fpgk | STIMUFEND | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Oct. 6, 2022 | In Use | |
70114-0101-01 | 70114-0101 | pegfilgrastim-cbqv | UDENYCA | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov. 2, 2018 | In Use | |
61314-0866-01 | 61314-0866 | pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Nov. 4, 2019 | In Use | |
67457-0833-06 | 67457-0833 | pegfilgrastim | Fulphila | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | July 9, 2018 | In Use | |
25021-0783-05 | 25021-0783 | palonosetron hydrochloride | palonosetron hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | June 15, 2018 | In Use | |
36000-0326-02 | 36000-0326 | palonosetron hydrochloride | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov. 12, 2021 | In Use | |
16729-0365-66 | 16729-0365 | palonosetron hydrochloride | palonosetron hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | March 23, 2018 | Nov. 30, 2022 | No Longer Used |
00069-0688-03 | 00069-0688 | palbociclib | Ibrance | 125.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
63539-0688-03 | 63539-0688 | palbociclib | Ibrance | 125.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
63539-0284-03 | 63539-0284 | palbociclib | Ibrance | 75.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
63539-0486-03 | 63539-0486 | palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 30, 2020 | In Use | |
47781-0595-07 | 47781-0595 | paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 27, 2017 | In Use | |
47781-0593-07 | 47781-0593 | paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 27, 2017 | Aug. 1, 2020 | No Longer Used |
47781-0594-07 | 47781-0594 | paclitaxel | Paclitaxel | 100.0 mg/16.7mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 27, 2017 | Jan. 1, 2020 | No Longer Used |
68001-0341-36 | 68001-0341 | oxaliplatin | oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb. 9, 2018 | Jan. 31, 2020 | No Longer Used |
68001-0341-37 | 68001-0341 | oxaliplatin | oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb. 9, 2018 | Jan. 31, 2020 | No Longer Used |
36000-0014-06 | 36000-0014 | ondansetron hydrochloride and dextrose | Ondansetron hydrochloride and dextrose | 32.0 mg/50mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | April 14, 2009 | Feb. 23, 2018 | No Longer Used |
61786-0699-02 | 61786-0699 | ondansetron hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 19, 2016 | In Use | |
43063-0746-12 | 43063-0746 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 17, 2017 | In Use | |
00904-6552-61 | 00904-6552 | ondansetron hydrochloride | ondansetron hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 26, 2006 | In Use | |
25021-0777-02 | 25021-0777 | ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 30, 2012 | In Use | |
51672-4091-03 | 51672-4091 | ondansetron hydrochloride | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 30, 2007 | In Use | |
67877-0169-30 | 67877-0169 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | In Use | |
67877-0170-30 | 67877-0170 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 25, 2007 | In Use | |
00173-0442-00 | 00173-0442 | ondansetron hydrochloride | Zofran | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Feb. 4, 1991 | Feb. 28, 2018 | No Longer Used |
00173-0442-02 | 00173-0442 | ondansetron hydrochloride | Zofran | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Feb. 4, 1991 | July 5, 2012 | No Longer Used |
00173-0446-00 | 00173-0446 | ondansetron hydrochloride | Zofran | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 11, 1993 | Feb. 28, 2019 | No Longer Used |
00173-0446-02 | 00173-0446 | ondansetron hydrochloride | Zofran | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 11, 1993 | Dec. 16, 2013 | No Longer Used |
00173-0446-04 | 00173-0446 | ondansetron hydrochloride | Zofran | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 11, 1993 | Sept. 22, 2011 | No Longer Used |
00173-0570-00 | 00173-0570 | ondansetron hydrochloride | ZOFRAN | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 1, 1999 | Feb. 28, 2018 | No Longer Used |
00173-0570-04 | 00173-0570 | ondansetron hydrochloride | ZOFRAN | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 1, 1999 | Sept. 22, 2011 | No Longer Used |
25021-0782-20 | 25021-0782 | ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 30, 2012 | Nov. 30, 2021 | No Longer Used |
50090-1015-00 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-01 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-02 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-03 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1015-04 | 50090-1015 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 28, 2014 | March 31, 2019 | In Use |
50090-1600-00 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 5, 2015 | May 31, 2019 | In Use |
50090-1600-01 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 5, 2015 | Jan. 31, 2018 | In Use |
Found 9,752 results in 7 milliseconds — Export these results